Neuberger Berman Group
SPRY icon

Neuberger Berman Group’s ARS Pharmaceuticals SPRY Stock Holding History

Neuberger Berman Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-324,877
Closed -$5.67M – 2142
2025
Q2 		$5.67M Buy
324,877
+7,530
+2% +$109K ﹤0.01% 934
2025
Q1 		$3.99M Buy
317,347
+30,501
+11% +$367K ﹤0.01% 976
2024
Q4 		$3.03M Buy
286,846
+40,911
+17% +$573K ﹤0.01% 1047
2024
Q3 		$3.57M Buy
+245,935
New +$2.93M ﹤0.01% 1011

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Neuberger Berman Group's SPRY Position: Q3 2025 in Review

Neuberger Berman Group sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 324,877 shares — an estimated $5.67M sold.

Neuberger Berman Group first reported a position in SPRY in Q3 2024 and held it in 4 quarters. The position peaked at $5.67M in Q2 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • Neuberger Berman Group reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Neuberger Berman Group sold 324,877 ARS Pharmaceuticals shares in Q3 2025, an estimated $5.67M.
  • Neuberger Berman Group first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Neuberger Berman Group's ARS Pharmaceuticals position peaked at $5.67M in Q2 2025.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Neuberger Berman Group's 13F filing for Q3 2025, filed 12 Nov 2025.